These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37685988)

  • 1. Report on the Effect of the Implementation of an Early Detection and Prevention of Cancer Program on Families at High Hereditary Risk-Concentrating on Patients Undergoing Genetic Diagnostics and Counseling in Central Poland.
    Kałużewski T; Kubiak I; Bednarek M; Sałamunia J; Kucharska D; Kępczyński Ł; Stempień M; Kubicki T; Trzciński R; Gordon-Sönmez Z; Bartosińska-Dyc A; Gach A; Kałużewski B
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study.
    Kowalik A; Siołek M; Kopczyński J; Krawiec K; Kalisz J; Zięba S; Kozak-Klonowska B; Wypiórkiewicz E; Furmańczyk J; Nowak-Ozimek E; Chłopek M; Macek P; Smok-Kalwat J; Góźdź S
    PLoS One; 2018; 13(7):e0201086. PubMed ID: 30040829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
    Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
    Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
    Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
    J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
    Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
    Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor risk consultation for predisposed women from high risk cancer families].
    Beckmann MW; Niederacher D; Bodden-Heidrich R; Goecke TO; Kuschel B; Achnoula M; Aba F; Schnürch HG; Bender HG
    Praxis (Bern 1994); 1998 Apr; 87(15):511-5. PubMed ID: 9608246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications.
    Casey MJ; Bewtra C; Lynch HT; Snyder CL; Stacey M
    Int J Gynecol Cancer; 2015 May; 25(4):650-6. PubMed ID: 25756400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
    Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
    Darooei M; Poornima S; Salma BU; Iyer GR; Pujar AN; Annapurna S; Shah A; Maddali S; Hasan Q
    Tumour Biol; 2017 Feb; 39(2):1010428317694303. PubMed ID: 28231738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
    Castéra L; Krieger S; Rousselin A; Legros A; Baumann JJ; Bruet O; Brault B; Fouillet R; Goardon N; Letac O; Baert-Desurmont S; Tinat J; Bera O; Dugast C; Berthet P; Polycarpe F; Layet V; Hardouin A; Frébourg T; Vaur D
    Eur J Hum Genet; 2014 Nov; 22(11):1305-13. PubMed ID: 24549055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.